Article

Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.

Pulmonary, Critical Care and Sleep Divisions, Tufts-New England Medical Center, Boston, Massachussets, USA.
Current Opinion in Pharmacology (impact factor: 6.86). 07/2005; 5(3):245-50. DOI:10.1016/j.coph.2004.12.008 pp.245-50
Source: PubMed

ABSTRACT Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators in experimental models that partially reverse established pulmonary arterial hypertension and blunt chronic pulmonary hypertension. In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or natriuretic peptide levels by enhancing intracellular cGMP and cGMP-mediated vasodilator effects. Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension.

0 0
 · 
0 Bookmarks
 · 
26 Views
  • Source
    Article: Immunohistochemical localisation of PDE5 in rat lung during pre- and postnatal development.
    Angela Scipioni, Mauro Giorgi, Valeria Nuccetelli, Stefania Stefanini
    [show abstract] [hide abstract]
    ABSTRACT: In mammalian lung, at the transition to extrauterine life, NO/cGMP signal transduction system is known to play crucial roles in the regulation of vascular resistance and is supposed to act in angiogenesis. PDE5, which is the most abundant cGMP metabolizing enzyme within the lung, is highly expressed in the perinatal period, but its localisation in the different pulmonary cells is still poorly known. In our research, PDE5 immunohistochemical distribution was investigated in foetal and neonatal rat lung. The highest expression of PDE5 was found in cells randomly located in the stroma; in newborns, in particular, many cells in the intersaccular walls were heavily labelled, while much lower staining levels were shown by smooth myocytes belonging to vessels and airways. On the basis of their immunoreactivity for alpha-SM actin and/or desmin, most of the heavily PDE5-positive cells were identified as interstitial myofibroblasts and transitional pericytes, while only a few were interpreted as interstitial lipofibroblasts.
    Journal of Biomedicine and Biotechnology 02/2009; 2009:932961. · 2.44 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

cGMP-mediated vasodilator effects
 
chronic pulmonary hypertension
 
experimental models
 
intracellular cGMP
 
modulate intracellular cGMP
 
natriuretic peptide levels
 
nitric oxide
 
patients
 
PDE5
 
PDE5 inhibitors
 
PDE5 inhibitors work
 
pulmonary arterial hypertension
 
pulmonary hemodynamics
 
pulmonary hypertension
 
Recent studies
 
reverse